Deutsche Tageszeitung - Disgraced surgeon on trial in Sweden over windpipe transplants

Disgraced surgeon on trial in Sweden over windpipe transplants


Disgraced surgeon on trial in Sweden over windpipe transplants
Disgraced surgeon on trial in Sweden over windpipe transplants / Photo: © KAROLINSKA UNIVERSITY HOSPITAL/AFP

An Italian doctor who made headlines for pioneering windpipe surgery went on trial in Sweden on Wednesday, charged with assault for performing the experimental procedure.

Change text size:

Paolo Macchiarini won praise in 2011 after claiming to have performed the world's first synthetic trachea transplants using stem cells while he was a surgeon at Stockholm's Karolinska Institute.

The procedure was hailed as a breakthrough in regenerative medicine.

But allegations soon emerged that the risky procedure had been carried out on at least one person who had not been critically ill at the time of the operation.

The 63-year-old appeared in court in a blue suit Wednesday, where he listened to translated audio as prosecutors listed the charges of "aggravated assault" against three patients.

- 'Disregard for science' -

The Karolinska Institute has confirmed that the three individuals have since died, but did not directly link the deaths to the operations.

"Macchiarini has carried out the surgery with complete disregard for science and tried experience," prosecutor Karin Lundstrom-Kron told the court.

As prosecutors presented their case they referenced both external and internal reviews of the case, including one published in 2016 by physician Kjell Asplund, who argued that Macchiarini should never have been employed by Karolinska in the first place.

"It is clear that this method has not worked," prosecutor Jim Westerberg said, adding that Macchiarini had embellished the benefits of the procedure.

Macchiarini, who took notes without showing much emotion, has maintained the operations constituted treatments and not experiments, and denied being criminally responsible.

"He contends that he has performed health care, cured and helped," Macchiarini's lawyer Bjorn Hurtig told AFP during a recess.

The prosecution's presentation of evidence is expected to continue over several days so the defence will likely not be able to present its side until next week.

But Hurtig said they had "high hopes" they would be able to counter the prosecution's evidence.

"There are quite a lot of gaps in that evidence and there is a lot of evidence that we argue are favourable to our view of things," he said.

- Downplayed risks -

In 2013, the Karolinska hospital suspended all transplants and refused to extend Macchiarini's contract as a surgeon.

A year later, several surgeons at the hospital filed a complaint alleging that Macchiarini had downplayed the risks of the procedure.

Macchiarini carried out three surgeries at Karolinska University Hospital in 2011 and 2012, using an artificial windpipe made of plastic and coating it with the patient's own stem cells.

Together with his colleagues, he performed a total of eight such transplants between 2011 and 2014, the five others taking place in Russia.

An external review in 2015 found Macchiarini guilty of research misconduct, but despite sacking him, the Karolinska Institute repeatedly defended him until 2018, when it found him and several other researchers guilty.

The university's principal stepped down over the scandal, as well as a number of other people.

Medical journal The Lancet in 2018 retracted two papers authored by Macchiarini.

The trial, held in the Solna district court near the Karolinska Institute, is scheduled to take place over 13 days.

(V.Sørensen--DTZ)

Featured

How to assess microplastics in our bodies? Scientists have a plan

How many tiny pieces of plastic are currently inside your body?

The Market Has Spoken: BridgeLink Surpasses 10,000 Downloads, Solidifying Status as the Global Standard for Open-Source Health Interoperability

MONTGOMERY, AL / ACCESS Newswire / January 27, 2026 / Innovar Healthcare today announced that BridgeLink, the open-source integration engine, has surpassed 10,000 enterprise downloads, a milestone that signals a decisive shift in the healthcare IT landscape. Following the market shift toward restrictive proprietary licensing for the industry's legacy engine, the healthcare community has decisively moved to BridgeLink as the premier open-source replacement.

MicroVision Announces Agreement to Acquire Luminar Assets to Accelerate Commercial Strategy and Expand Product Portfolio

REDMOND, WASHINGTON / ACCESS Newswire / January 27, 2026 / MicroVision, Inc. (NASDAQ:MVIS), a technology pioneer delivering advanced perception solutions in autonomy and mobility, today announced that it had entered into an agreement to acquire certain assets from Luminar Technologies, Inc., including IP and inventory related to the Iris and Halo lidar sensors, key engineering and operations talent, and certain commercial contracts and orders.

Symetrix Unveils Cognio: The Next-Generation Audio, Video, and Control Platform

With breakthrough distributed architecture and wire-free design workflows, Cognio redefines how AV systems are designed, deployed, and operated; see it for the first time at ISE 2026

Change text size: